Skip to main content

Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment

Annals of Hematology volume 100, pages 2557–2566 (2021)Cite this article

Abstract

Recent studies have shown that approximately 50% of patients with chronic myeloid leukemia (CML) receiving tyrosine kinase inhibitor (TKI) therapy with a sustained deep molecular response (DMR) (BCR-ABL1IS ≤ 0.01%) can achieve treatment-free remission (TFR, stopping TKI without relapse) and that prior interferon (IFN)-α therapy and higher NK cell counts at and after TKI discontinuation are associated with TFR. We recently reported that post-TKI discontinuation of IFN-α therapy could prevent molecular relapse (MR, BCR-ABL1IS > 0.1%). Here, we evaluated whether NK cells are associated with MR and investigated the effects of post-TKI discontinuation IFN-α therapy on lymphocyte subsets. A total of 34 patients measuring blood lymphocyte subclasses were included. In the 22 patients who did not receive IFN-α therapy, at 1 month after TKI discontinuation, the nonrelapsed patients showed a significantly higher proportion and count of NK cells than the relapsed patients. In particular, the proportion and count of CD56dim NK cells were significantly higher in the nonrelapsed patients than in the relapsed patients. In the 12 patients who received IFN-α therapy, the level of CD56bright NK cells increased significantly after 3 and 6 months of IFN-α therapy. In summary, NK cells, in particular CD56dim NK cells, were associated with MR after TKI discontinuation in patients with CML. Additionally, IFN-α therapy gradually increased the level of CD56bright NK cells in patients with CML.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Heisterkamp N, Stephenson JR, Groffen J, Hansen PF, de Klein A, Bartram CR, Grosveld G (1983) Localization of the c-ab1 oncogene adjacent to a translocation break point in chronic myelocytic leukaemia. Nature 306:239–242. https://doi.org/10.1038/306239a0

    CAS  Article  PubMed  Google Scholar 

  2. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, Bhatnagar B, Curtin P, DeAngelo DJ, Gotlib J, Hobbs G, Jagasia M, Kantarjian HM, Maness L, Metheny L, Moore JO, Pallera A, Pancari P, Patnaik M, Purev E, Rose MG, Shah NP, Smith BD, Snyder DS, Sweet KL, Talpaz M, Thompson J, Yang DT, Gregory KM, Sundar H (2018) Chronic myeloid leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 16:1108–1135. https://doi.org/10.6004/jnccn.2018.0071 (version 1.2019)

    Article  PubMed  Google Scholar 

  3. Druker BJ, Lee SJ (2007) Chapter 43: Chronic leukemias: Section 1: Chronic myelogenous leukemia//cancer principles and practice of oncology

  4. Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, Larson RA, Lipton JH, Mahon FX, Mayer J, Nicolini F, Niederwieser D, Pane F, Radich JP, Rea D, Richter J, Rosti G, Rousselot P, Saglio G, Saußele S, Soverini S, Steegmann JL, Turkina A, Zaritskey A, Hehlmann R (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34:966–984. https://doi.org/10.1038/s41375-020-0776-2

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  5. Kalmanti L, Saussele S, Lauseker M, Müller MC, Dietz CT, Heinrich L, Hanfstein B, Proetel U, Fabarius A, Krause SW, Rinaldetti S, Dengler J, Falge C, Oppliger-Leibundgut E, Burchert A, Neubauer A, Kanz L, Stegelmann F, Pfreundschuh M, Spiekermann K, Scheid C, Pfirrmann M, Hochhaus A, Hasford J, Hehlmann R (2015) Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV. Leukemia 29:1123–1132. https://doi.org/10.1038/leu.2015.36

    CAS  Article  PubMed  Google Scholar 

  6. Larson RA, Hochhaus A, Hughes TP, Clark RE, Etienne G, Kim DW, Flinn IW, Kurokawa M, Moiraghi B, Yu R, Blakesley RE, Gallagher NJ, Saglio G, Kantarjian HM (2012) Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-up. Leukemia 26:2197–2203. https://doi.org/10.1038/leu.2012.134

    CAS  Article  PubMed  Google Scholar 

  7. Wang J, Shen ZX, Saglio G, Jin J, Huang H, Hu Y, Du X, Li J, Meng F, Zhu H, Hu J, Wang J, Hou M, Hertle S, Menssen HD, Ortmann CE, Tribouley C, Yuan Y, Baccarani M, Huang X (2015) Phase 3 study of nilotinib vs imatinib in Chinese patients with newly diagnosed chronic myeloid leukemia in chronic phase: ENESTchina. Blood 125:2771–2778. https://doi.org/10.1182/blood-2014-09-601674

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  8. Cortes JE, Saglio G, Kantarjian HM, Baccarani M, Mayer J, Boqué C, Shah NP, Chuah C, Casanova L, Bradley-Garelik B, Manos G, Hochhaus A (2016) Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 34:2333–2340. https://doi.org/10.1200/JCO.2015.64.8899

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. Mahon FX, Réa D, Guilhot J, Guilhot F, Huguet F, Nicolini F, Legros L, Charbonnier A, Guerci A, Varet B, Etienne G, Reiffers J, Rousselot P, Français I, des LeucémiesMyéloïdesChroniques, (2010) Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial. Lancet Oncol 11:1029–1035. https://doi.org/10.1016/S1470-2045(10)70233-3

    CAS  Article  PubMed  Google Scholar 

  10. Saussele S, Richter J, Guilhot J, Gruber FX, Hjorth-Hansen H, Almeida A, Janssen JJWM, Mayer J, Koskenvesa P, Panayiotidis P, Olsson-Strömberg U, Martinez-Lopez J, Rousselot P, Vestergaard H, Ehrencrona H, Kairisto V, MachováPoláková K, Müller MC, Mustjoki S, Berger MG, Fabarius A, Hofmann WK, Hochhaus A, Pfirrmann M, Mahon FX, EURO-SKI investigators (2018) Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol 19:747–757. https://doi.org/10.1016/S1470-2045(18)30192-X

    CAS  Article  PubMed  Google Scholar 

  11. Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP (2013) Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood 122:515–522. https://doi.org/10.1182/blood-2013-02-483750

    CAS  Article  PubMed  Google Scholar 

  12. Imagawa J, Tanaka H, Okada M, Nakamae H, Hino M, Murai K, Ishida Y, Kumagai T, Sato S, Ohashi K, Sakamaki H, Wakita H, Uoshima N, Nakagawa Y, Minami Y, Ogasawara M, Takeoka T, Akasaka H, Utsumi T, Uike N, Sato T, Ando S, Usuki K, Morita S, Sakamoto J, Kimura S, DADI Trial Group (2015) Discontinuation of dasatinib in patients with chronic myeloid leukaemia who have maintained deep molecular response for longer than 1 year (DADI trial): a multicentre phase 2 trial. Lancet Haematol 2:e528–e535. https://doi.org/10.1016/S2352-3026(15)00196-9

    Article  PubMed  Google Scholar 

  13. Rea D, Nicolini FE, Tulliez M, Guilhot F, Guilhot J, Guerci-Bresler A, Gardembas M, Coiteux V, Guillerm G, Legros L, Etienne G, Pignon JM, Villemagne B, Escoffre-Barbe M, Ianotto JC, Charbonnier A, Johnson-Ansah H, Noel MP, Rousselot P, Mahon FX, France Intergroupe des LeucémiesMyéloïdesChroniques (2017) France intergroupe des leucémies Myéloïdes chroniques. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study. Blood 129:846–854. https://doi.org/10.1182/blood-2016-09-742205

    CAS  Article  PubMed  Google Scholar 

  14. Hochhaus A, Masszi T, Giles FJ, Radich JP, Ross DM, Gómez Casares MT, Hellmann A, Stentoft J, Conneally E, García-Gutiérrez V, Gattermann N, Wiktor-Jedrzejczak W, le Coutre PD, Martino B, Saussele S, Menssen HD, Deng W, Krunic N, Bedoucha V, Saglio G (2017) Treatment-free remission following frontline nilotinib in patients with chronic myeloid leukemia in chronic phase: results from the ENESTfreedom study. Leukemia 31:1525–1531. https://doi.org/10.1038/leu.2017.63

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. Rea D, Henry G, Khaznadar Z, Etienne G, Guilhot F, Nicolini F, Guilhot J, Rousselot P, Huguet F, Legros L, Gardembas M, Dubruille V, Guerci-Bresler A, Charbonnier A, Maloisel F, Ianotto JC, Villemagne B, Mahon FX, Moins-Teisserenc H, Dulphy N, Toubert A (2017) Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica 102:1368–1377. https://doi.org/10.3324/haematol.2017.165001

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  16. Ilander M, Olsson-Strömberg U, Schlums H, Guilhot J, Brück O, Lähteenmäki H, Kasanen T, Koskenvesa P, Söderlund S, Höglund M, Markevärn B, Själander A, Lotfi K, Dreimane A, Lübking A, Holm E, Björeman M, Lehmann S, Stenke L, Ohm L, Gedde-Dahl T, Majeed W, Ehrencrona H, Koskela S, Saussele S, Mahon FX, Porkka K, Hjorth-Hansen H, Bryceson YT, Richter J, Mustjoki S (2017) Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia 31:1108–1116. https://doi.org/10.1038/leu.2016.360

    CAS  Article  PubMed  Google Scholar 

  17. Kong J, Qin Y-Z, Shi H-X, Lai Y-Y, Liu K-Y, Huang X-J, Jiang H (2021) Interferon-α may help prevent molecular relapse of chronic myeloid leukemia after the discontinuation of tyrosine kinase inhibitors. Ther Adv Hematol 12:1–11. https://doi.org/10.1177/2040620720986643

    CAS  Article  Google Scholar 

  18. Burchert A, Müller MC, Kostrewa P, Erben P, Bostel T, Liebler S, Hehlmann R, Neubauer A, Hochhaus A (2010) Sustained molecular response with interferon alfa maintenance after induction therapy with imatinib plus interferon alfa in patients with chronic myeloid leukemia. J Clin Oncol 28:1429–1435. https://doi.org/10.1200/JCO.2009.25.5075

    CAS  Article  PubMed  Google Scholar 

  19. Mahon FX, Delbrel X, Cony-Makhoul P, Fabères C, Boiron JM, Barthe C, Bilhou-Nabéra C, Pigneux A, Marit G, Reiffers J (2002) Follow-up of complete cytogenetic remission in patientswith chronic myeloid leukemia after cessation of interferon alfa. J Clin Oncol 20:214–220. https://doi.org/10.1200/JCO.2002.20.1.214

    CAS  Article  PubMed  Google Scholar 

  20. Kreutzman A, Rohon P, Faber E, Indrak K, Juvonen V, Kairisto V, Voglová J, Sinisalo M, Flochová E, Vakkila J, Arstila P, Porkka K, Mustjoki S (2011) Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE 6:e23022. https://doi.org/10.1371/journal.pone.0023022

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  21. Kärre K, Ljunggren HG, Piontek G, Kiessling R (1986) Selective rejection of H-2-deficient lymphoma variants suggests alternative immune defence strategy. Nature 319:675–678. https://doi.org/10.1038/319675a0

    Article  PubMed  Google Scholar 

  22. Najima Y, Yoshida C, Iriyama N, Fujisawa S, Wakita H, Chiba S, Okamoto S, Kawakami K, Takezako N, Kumagai T, Ohyashiki K, Taguchi J, Yano S, Igarashi T, Kouzai Y, Morita S, Sakamoto J, Sakamaki H, Inokuchi K (2018) Regulatory T cell inhibition by dasatinib is associated with natural killer cell differentiation and a favorable molecular response-The final results of the D-first study. Leuk Res 66:66–72. https://doi.org/10.1016/j.leukres.2018.01.010

    CAS  Article  PubMed  Google Scholar 

  23. Larmonier N, Marron M, Zeng Y, Cantrell J, Romanoski A, Sepassi M, Thompson S, Chen X, Andreansky S, Katsanis E (2007) Tumor-derived CD4(+)CD25(+) regulatory T cell suppression of dendritic cell function involves TGF-beta and IL-10. Cancer Immunol Immunother 56:48–59. https://doi.org/10.1007/s00262-006-0160-8

    CAS  Article  PubMed  Google Scholar 

  24. Szczepanski MJ, Szajnik M, Czystowska M, Mandapathil M, Strauss L, Welsh A, Foon KA, Whiteside TL, Boyiadzis M (2009) Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia. Clin Cancer Res 15:3325–3332. https://doi.org/10.1158/1078-0432.CCR-08-3010

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  25. Idris SZ, Hassan N, Lee LJ, Noor MdS, Osman R, Abdul-Jalil M, Nordin AJ, Abdullah M (2015) Increased regulatory T cells in acute lymphoblastic leukemia patients. Hematology 20:523–529. https://doi.org/10.1179/1607845415Y.0000000025

    CAS  Article  PubMed  Google Scholar 

  26. D’Arena G, Laurenti L, Minervini MM, Deaglio S, Bonello L, De Martino L, De Padua L, Savino L, Tarnani M, De Feo V, Cascavilla N (2011) Regulatory T-cell number is increased in chronic lymphocytic leukemia patients and correlates with progressive disease. Leuk Res 35:363–368. https://doi.org/10.1016/j.leukres.2010.08.010

    Article  PubMed  Google Scholar 

  27. Anguille S, Lion E, Willemen Y, Van Tendeloo VF, Berneman ZN, Smits EL (2011) Interferon-α in acute myeloid leukemia: an old drug revisited. Leukemia 25:739–748. https://doi.org/10.1038/leu.2010.324

    CAS  Article  PubMed  Google Scholar 

  28. Alves R, McArdle SEB, Vadakekolathu J, Gonçalves AC, Freitas-Tavares P, Pereira A, Almeida AM, Sarmento-Ribeiro AB, Rutella S (2020) Flow cytometry and targeted immune transcriptomics identify distinct profiles in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors with or without interferon-α. J Transl Med 18:2. https://doi.org/10.1186/s12967-019-02194-x

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  29. Michel T, Poli A, Cuapio A, Briquemont B, Iserentant G, Ollert M, Zimmer J (2016) Human CD56bright NK cells: an update. J Immunol 196:2923–2931. https://doi.org/10.4049/jimmunol.1502570

    CAS  Article  PubMed  Google Scholar 

  30. Wagner JA, Rosario M, Romee R, Berrien-Elliott MM, Schneider SE, Leong JW, Sullivan RP, Jewell BA, Becker-Hapak M, Schappe T, Abdel-Latif S, Ireland AR, Jaishankar D, King JA, Vij R, Clement D, Goodridge J, Malmberg KJ, Wong HC, Fehniger TA (2017) CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. J Clin Invest 127:4042–4058. https://doi.org/10.1172/JCI90387

    Article  PubMed  PubMed Central  Google Scholar 

  31. Ilander M, Kreutzman A, Rohon P, Melo T, Faber E, Porkka K, Vakkila J, Mustjoki S (2014) Enlarged memory T-cell pool and enhanced Th1-type responses in chronic myeloid leukemia patients who have successfully discontinued IFN-α monotherapy. PLoS ONE 9:e87794. https://doi.org/10.1371/journal.pone.0087794

    CAS  Article  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

The authors thank the faculty members who helped with this study.

Funding

This work was supported by the Capital Characteristic Clinic Project Foundation (Z181100001718126).

Author information

Authors and Affiliations

  1. Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Centre for Hematologic Disease, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, No. 11, Xizhimen South Street, Xicheng District, Beijing, 100044, People’s Republic of China

    Jun Kong, Ya-zhen Qin, Xiao-Su Zhao, Yue Hou, Kai-yan Liu, Xiao-jun Huang & Hao Jiang

Authors
  1. Jun Kong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ya-zhen Qin
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiao-Su Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Yue Hou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Kai-yan Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Xiao-jun Huang
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Hao Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Jun Kong and Hao Jiang designed the study, and Jun Kong analyzed and interpreted the data and wrote the manuscript. Ya-zhen Qin and Xiao-su Zhao performed the RT-qPCR and FCM experiments.

Corresponding author

Correspondence to Hao Jiang.

Ethics declarations

Ethics approval

All procedures were conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, revised in 2008.

Consent to participate

Informed consent was obtained from all individual participants included in the study.

Conflicts of interest

The authors have no conflicts of interest to declare that are relevant to the content of this article.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Kong, J., Qin, Yz., Zhao, XS. et al. Profiles of NK cell subsets are associated with successful tyrosine kinase inhibitor discontinuation in chronic myeloid leukemia and changes following interferon treatment. Ann Hematol 100, 2557–2566 (2021). https://doi.org/10.1007/s00277-021-04606-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-021-04606-9

Keywords

  • Chronic myeloid leukemia
  • Tyrosine kinase inhibitor
  • Treatment-free remission
  • Natural killer cell
  • Interferon